Generic Name and Formulations:
Oxandrolone 2.5mg+, 10mg; tabs (+scored).
Gemini Laboratories, LLC
Indications for OXANDRIN:
As an adjunct to promote weight gain after extensive surgery, chronic infections, severe trauma, and without definite cause, to offset protein catabolism associated with prolonged corticosteroid administration, and for relief of osteoporotic bone pain.
Individualize. 2.5–20mg daily given in 2–4 divided doses. Treat for 2–4 weeks; may repeat intermittently as needed. Elderly: 5mg twice daily.
≤0.1mg/kg/day; may repeat intermittently as needed.
Breast (women with hypercalcemia, men) or prostate carcinoma. Nephrosis. Hypercalemia. Pregnancy (Cat.X).
Peliosis hepatis. Liver cell tumors. Blood lipid changes.
Risk of peliosis hepatis, liver cell tumors, blood lipid changes associated with atherosclerosis. Discontinue if cholestatic hepatitis, jaundice, abnormal liver function tests, or hypercalcemia occurs. Cardiovascular disease. COPD. Edematous conditions. Hepatic or renal dysfunction. Monitor hepatic function, serum lipids, Hgb/Hct, and bone age (children) periodically. Monitor for signs of virilization in women; discontinue if mild virilism occurs to prevent irreversible condition. Elderly. Young children. Nursing mothers: not recommended.
May potentiate warfarin (monitor INR/PT), oral hypoglycemics. Increased risk of edema with ACTH, corticosteroids. May suppress clotting factors II, V, VII and X. May decrease thyroxine-binding globulin and radioactive iodine uptake.
Peliosis hepatis, premature epiphyseal closure in children, edema, dyslipidemia, hepatic carcinoma, prostatic hypertrophy or carcinoma, gynecomastia, priapism, oligospermia, jaundice, hirsutism, virilization, menstrual irregularities, male pattern baldness, acne, polycythemia, excitation, depression, altered libido, fluid and electrolyte disturbances, decreased glucose tolerance.
Tabs 2.5mg—100; 10mg—60
Clinical Pain Advisor Articles
- Aetna-CVS Merger Approved
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Managing Comorbid Opioid and Alcohol Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- What Do Clinicians Do in Response to Aberrant Urine Drug Test Results?
- Photo Elicitation on Social Media Can Provide Perspective to Patients With Chronic Pain
- Patients Assume Postoperative Opioids Are Best for Pain Relief
- Educational Disabilities More Likely With Neonatal Abstinence Syndrome
- When Will Medicine Join the Women's Movement?